Ceftazidime-avibactam: new rules for the game against multidrug-resistant gram-negative bacteria
Open Access
- 1 January 2018
- journal article
- Published by Interregional Association for Clinical Microbiology and Antimicrobial Chemotherapy in Clinical Microbiology and Antimicrobial Chemotherapy
- Vol. 20 (1)
- https://doi.org/10.36488/cmac.2018.1.24-34
Abstract
The rapid spread of multidrug-resistant Gram-negative bacteria in hospital settings all over the world makes a demand for the new options to overcome antimicrobial resistance. Ceftazidime-avibactam is the first approved antibiotic that contains a new beta-lactamase inhibitor with unique properties. This review provides insight into the spectrum of activity, pharmacological characteristics, data on efficacy and safety of ceftazidime-avibactam obtained from the clinical trials and real clinical practice, as well as prospects for further studies and clinical application of this new antimicrobial agent.Keywords
This publication has 35 references indexed in Scilit:
- New β-Lactamase Inhibitors in the ClinicInfectious Disease Clinics of North America, 2016
- Investigations on recyclisation and hydrolysis in avibactam mediated serine β-lactamase inhibitionOrganic & Biomolecular Chemistry, 2016
- In Vitro Antibacterial Activity of the Ceftazidime-Avibactam Combination against Enterobacteriaceae, Including Strains with Well-Characterized β-LactamasesAntimicrobial Agents and Chemotherapy, 2015
- Combating multidrug-resistant Gram-negative bacterial infectionsExpert Opinion on Investigational Drugs, 2013
- Ceftazidime-Avibactam: a Novel Cephalosporin/β-lactamase Inhibitor CombinationDrugs, 2013
- The ABCD’s of β-lactamase nomenclatureJournal of Infection and Chemotherapy, 2013
- Avibactam is a covalent, reversible, non–β-lactam β-lactamase inhibitorProceedings of the National Academy of Sciences of the United States of America, 2012
- In Vitro Antibacterial Activity of the Ceftazidime-Avibactam (NXL104) Combination against Pseudomonas aeruginosa Clinical IsolatesAntimicrobial Agents and Chemotherapy, 2012
- Inhibitor Resistance in the KPC-2 β-Lactamase, a Preeminent Property of This Class A β-LactamaseAntimicrobial Agents and Chemotherapy, 2010
- Three Decades of β-Lactamase InhibitorsClinical Microbiology Reviews, 2010